| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0960-9776(09)70291-7 |
| P698 | PubMed publication ID | 19914535 |
| P2093 | author name string | I E Smith | |
| P2860 | cites work | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group | Q27824835 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 | ||
| Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
| Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer | Q34496969 | ||
| American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer | Q36678853 | ||
| Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. | Q50773376 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| P304 | page(s) | S146-9 | |
| P577 | publication date | 2009-10-01 | |
| P1433 | published in | The Breast | Q7719928 |
| P1476 | title | Targeting HER2 in the adjuvant setting: dealing with new standards and with open questions | |
| P478 | volume | 18 Suppl 3 |
| Q24657145 | Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 | cites work | P2860 |
Search more.